Functional Characterization of Cholera Toxin Inhibitors Using Human Intestinal Organoids

Area of Science:

• Biomedical research
• Toxicology
• Drug discovery

Background:

• Preclinical drug testing requires accurate models to reduce animal experimentation.
• Pathogen-derived toxins, like cholera toxin, pose significant health risks.
• Developing effective inhibitors is crucial for treating toxin-induced diseases.

Purpose of the Study:

• To evaluate the potency of multivalent cholera toxin inhibitors using a novel preclinical model.
• To establish an organoid-based assay for quantitative assessment of drug efficacy.
• To demonstrate the utility of intestinal organoids in reducing animal testing.

Main Methods:

• Utilized human intestinal organoids as a disease-relevant preclinical model.
• Developed and applied a quantitative swelling assay to measure inhibitor potency.
• Determined IC50 values across a broad range of inhibitor concentrations.

Main Results:

• The organoid-based swelling assay successfully quantified the potency of cholera toxin inhibitors.
• Achieved accurate IC50 determinations spanning from picomolar to millimolar concentrations (15 pM to 9 mM).
• Demonstrated the assay's capability to evaluate a wide spectrum of inhibitor potencies.

Conclusions:

• Intestinal organoids provide a valuable platform for preclinical drug testing against pathogen toxins.
• The organoid swelling assay is a robust and quantitative method for evaluating inhibitor efficacy.
• This approach significantly reduces reliance on animal models for drug development.